Industry News

Cardinal Health plans to release first-quarter financial results for its fiscal year 2017 on Oct. 31 prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern. To access the webcast and corresponding slide presentation, go to the Investor Relations page at"/>
Cardinal Health to Webcast Discussion of First-Quarter Results for Fiscal Year 2017 on Oct. 31
Neurotrope, Inc., a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, today announced that it has appointed its Chief Scientific Officer, Dr. Daniel Alkon, to the additional role of President. After approximately 30 years directing programs on the molecular basis of associative memory at the National Neurologic Institute of NIH, and another approximately 15 years as the Founding..."/>
Dr. Daniel Alkon Appointed President of Neurotrope, Inc.
Invitae Corporation, a genetic information company, is participating in the National Society of Genetic Counselors 35th Annual Education Conference in Seattle, highlighting new research on genetic testing for preventive care and new strategies for providing remote access to genetic counseling services. NSGC is the largest scientific session for genetic counselors. Invitae’ s presenters will discuss:."/>
Invitae Presenting Research on Genetic Test Panels, Increasing Access to Genetic Counseling at the National Society of Genetic Counselors 35th Annual Education Conference
Relmada Therapeutics, Inc., a clinical-stage company developing novel therapies for the treatment of central nervous system diseases, today announced that Dr. Richard Mangano, the company's chief scientific officer, will participate in a panel of thought leaders regarding N-methyl-D-aspartate receptor antagonists as a new therapeutic option to treat depression. The panel discussion will be held at the Neuro Advance Boston Conference on..."/>
Relmada Therapeutics' Chief Scientific Officer Dr. Richard Mangano to Speak about d-Methadone as a Potential Rapid Acting Antidepressant at Neuro Advance Boston
Genomic Health, Inc. today announced that the company will present results from nine studies at the European Society for Medical Oncology 2016 Congress, which will take place October 7-11 at the Bella Center in Copenhagen, Denmark. Analytical validation study results for the recently launched Oncotype SEQ™ Liquid Select test. Oncotype SEQ is the first non-invasive liquid biopsy test that the company is delivering through its..."/>
Genomic Health Reinforces Global Leadership in Genomic-based Diagnostics with Presentation of Nine Personalized Medicine Studies Conducted in Six Countries at ESMO 2016 Congress
Image Protect Inc. announced today it has executed exclusive contracts with six of the top photo producers in the world. This brings the total number of images to be monitored for copyright protection to 50 MM, up from 1 MM in 2015. By leveraging over 30 years of professional experience in the photo industry, Image Protect has tapped into the market for monetizing millions of copyright violations worldwide."/>
Image Protect Inc. Executes Significant Industry Contracts in 2016
Dextera Surgical Inc. today announced the company’ s schedule of key lecture presentations at the 30 th European Association for Cardio-Thoracic Surgery annual meeting, the largest gathering of cardiothoracic surgeons in the world, to be held Oct. 1– 5 at the Centre Convencions Internacional de Barcelona in Barcelona, Spain.. Innovative approaches to cardiothoracic procedures using the company’ s MicroCutter 5/ 80 surgical stapling technology..."/>
Dextera Surgical’s MicroCutter Technology to be Featured in Presentations at EACTS Annual Conference
Premier, the second largest healthcare Group Purchasing Organization in the U.S. Effective October 1, 2016, SCA will provide Tork paper towels, tissues, napkins and dispensers to Premier's network of approximately 3,600 member hospitals and 120,000 alternate site..."/>
SCA Joins Supply Network of Leading Healthcare Group Purchasing Organization Premier
Cascadian Therapeutics, a clinical-stage biopharmaceutical company, today announced two upcoming poster presentations on tucatinib, the Company’ s lead product candidate for the treatment of HER2+ breast cancer, at the European Society of Medical Oncology 2016 Congress being held October 7 -11, 2016 in Copenhagen, Denmark.. Title: Cutaneous responses in Her-2+ metastatic breast cancer on phase 1 b study of ONT-380, an oral HER2-specific inhibitor in..."/>
Cascadian Therapeutics Announces Poster Presentations on Tucatinib at the European Society of Medical Oncology (ESMO) 2016 Congress
Immune Design, a clinical-stage immunotherapy company focused on cancer, today announced the application of its GLAAS discovery platform in Sanofi’ s Phase 1 clinical trial evaluating a novel therapeutic candidate for the treatment of peanut allergy. The trial follows an exclusive license agreement with Immune Design to discover, develop and commercialize products to treat a peanut allergy utilizing the company’ s GLAAS..."/>
Immune Design Announces Advancement of First GLAAS™-based Allergy Program into Clinical Development
TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age? related macular degeneration and fibrotic diseases, today announced a strategic licensing collaboration with Janssen..."/>
TRACON Pharmaceuticals Announces a Strategic Licensing Collaboration for Two Janssen Oncology Assets and a $5 Million Equity Investment from Johnson & Johnson Innovation – JJDC, Inc.
GenVec, Inc., a clinical-stage gene delivery company, announced that Douglas E. Brough, Ph.D., the company's chief scientific officer, will present " Exploring the AdenoVerse™ Platform for New Advanced Cell and Gene Therapies", a brief review of GenVec's technology platform, at the 2016 Cell& Gene Meeting on the Mesa. This presentation will highlight new data that demonstrate the utility of select AdenoVerse vectors for efficient gene..."/>
GenVec To Present At 2016 Cell & Gene Meeting On The Mesa
Vycor Medical, Inc. reports that a new peer-reviewed study published in "BioMed Research International" shows improvements in visual search following the use of NovaVision's NeuroEyeCoach. The three-centre study was conducted by the School of Psychology of University of Aberdeen, the Neuromotor and Cognitive Rehabilitation Research Centre of University of Verona, and the Department of Psychology of University of Munich."/>
New Clinical Study on NeuroEyeCoach Conclusively Supports Meaningful Improvement in Eye Movement Efficiency
Clovis Oncology, Inc. today announced that data from its rucaparib program in ovarian cancer will be..."/>
Clovis Oncology Announces Rucaparib Data Presentations at ESMO 2016 Congress
ARIAD Pharmaceuticals, Inc. today announced that its partner Otsuka Pharmaceutical Co., Ltd. has received approval from the Japanese Pharmaceuticals and Medical Devices Agency for Iclusig ® for the treatment of chronic myeloid leukemia resistant or intolerant to preceding drug treatment and relapsed or treatment resistant Philadelphia chromosome-positive acute lymphoblastic leukemia."/>
ARIAD Announces Regulatory Approval for Iclusig® (ponatinib) in Japan
Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic and serious inflammatory and fibrotic diseases, announced today that Professor Derek Gilroy, Ph.D. presented data on the effects of Resunab in a model of inflammation in healthy volunteers on September 28, 2016. The presentation was made at the 6th European Workshop on Lipid Mediators at Goethe University in Frankfurt am Main, Germany."/>
Corbus Announces Data on Effects of Resunab (JBT-101) in a Clinical Research Model of Resolution of Inflammation
Dermira, Inc., a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that data from its DRM04 Phase 3 clinical program in patients with primary axillary hyperhidrosis will be presented in a late-breaking news session at the 25 th European Academy of Dermatology and Venereology Congress, taking..."/>
Dermira to Present Data from DRM04 Phase 3 Clinical Trials at Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
Neogen announced on Tuesday its net income of USD9.89m for the Q1 2017 fiscal year ended 31 August. This marks an increase of 6% from the prior year's first quarter income of USD9, 323,000, or USD0.25 per share. Revenues of USD83.645m were collected for the first quarter of its 2017 fiscal year, a rise of 12% over revenues of USD74.86m in the first quarter of last year."/>
Neogen Corporation posts increase of 6% in net income and 12% in revenues
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, today announced that preclinical and Phase 1 clinical data describing XPO1 inhibition with selinexor, the Company’ s lead, oral Selective Inhibitor of Nuclear..."/>
Karyopharm Publishes Preclinical and Phase 1 Clinical Data for Selinexor in Ovarian Cancer in Clinical Cancer Research Publication
Quidel Corporation reported on Tuesday the receipt of 510 approval from the US Food and Drug Administration to market its Solana Influenza A+ B assay in the diagnosis of Influenza A and B infections for the upcoming 2016-2017 flu season. The company will market the Solana Influenza A+ B assay for the detection of nucleic acids isolated from nasal and nasopharyngeal swabs from patients with signs and symptoms of respiratory infection to aid in the..."/>
Quidel passes US FDA clearance for launch of Solana Influenza A+B Assay
Proteostasis Therapeutics, Inc., a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis, today announced the appointment of Naimish Patel, M.D., C.M., and Elizabeth Tullis, M.D., FRCPC, to its clinical advisory board. Patel is currently a Project Leader in Respiratory, Inflammation and Autoimmunity iMED and Senior Medical Director for AstraZeneca..."/>
Proteostasis Therapeutics Appoints Naimish Patel, M.D., C.M., and Elizabeth Tullis, M.D., FRCPC, to its Clinical Advisory Board
Aerie Pharmaceuticals, Inc., today announced that the Company will host a live webcast of its Investor Day taking place on Wednesday, October 5, 2016 at 12:00p.m. ET in New York, NY. To view the slide presentation and listen to the webcast please visit our website at"/>
Aerie Pharmaceuticals to Host Investor Day on October 5, 2016

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology756 Articles
Consumer Discretionary664 Articles
Financials531 Articles
Health Care434 Articles
Industrials426 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at